PDL BioPharma, Inc. Nonstatutory Inducement Stock Option Agreement (Amended 11/15/19)Inducement Stock Option Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
PDL BioPharma, Inc., has granted to Participant named in the Nonstatutory Inducement Stock Option Grant Notice (the “Notice”) to which this Nonstatutory Inducement Stock Option Agreement (this “Agreement”) is attached an option (the “Option”) to purchase certain shares of Common Stock upon the terms and conditions set forth in the Notice and this Agreement. By signing the Notice, the Participant: (a) acknowledges receipt of and represents that Participant has read and is familiar with the Notice and this Agreement and the current prospectus under the registration statement filed with the Securities and Exchange Commission (the “Prospectus”) which covers the Option, (b) accepts the Award subject to all of the terms and conditions of the Notice and this Agreement and (c) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Notice and this Agreement.
PDL BioPharma, Inc. Restricted Stock Agreement Amendment AcknowledgmentRestricted Stock Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
The Board of PDL BioPharma, Inc., has on November 15, 2019, amended the Restricted Stock Agreement applicable to the attached Restricted Stock Grant Notice(s) pursuant to Section 3(b)(viii) of the Equity Incentive Plan, with the intent that such amended Restricted Stock Agreement shall be applicable thereto. The Participant acknowledges, agrees and accepts the amended Restricted Stock Agreement as governing the awards represented in the attached Notice(s):
PDL BioPharma, Inc. Inducement Restricted Stock Agreement (Amended 11/15/19)Inducement Restricted Stock Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
PDL BioPharma, Inc., has granted to Participant named in the Inducement Restricted Stock Grant Notice (the “Notice”) to which this Inducement Restricted Stock Agreement (this “Agreement”) is attached an Award of Shares subject to the terms and conditions set forth in the Notice and this Agreement. By signing the Notice, the Participant: (a) acknowledges receipt of and represents that Participant has read and is familiar with the Notice and this Agreement and the current prospectus under the registration statement filed with the Securities and Exchange Commission (the “Prospectus”) which covers the Shares, (b) accepts the Award subject to all of the terms and conditions of the Notice and this Agreement and (c) agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Notice and this Agreement.
PDL BioPharma, Inc. Restricted Stock Agreement (Amended 11/15/19)Restricted Stock Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
PDL BioPharma, Inc. (the “Company”) has granted to the Participant named in the Restricted Stock Grant Notice (the “Notice”) to which this Restricted Stock Agreement (this “Agreement”) is attached an Award of Shares subject to the terms and conditions set forth in the Notice and this Agreement. The Award has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Company’s Amended and Restated 2005 Equity Incentive Plan (as amended to date, the “Plan”), the provisions of which are incorporated herein by reference. By signing the Notice, the Participant: (a) acknowledges receipt of and represents that Participant has read and is familiar with the Notice, this Agreement and the Plan and the current prospectus for the Plan (the “Prospectus”), (b) accepts the Award subject to all of the terms and conditions of the Notice, this Agreement and the Plan and (c) agrees to accept as binding, conclusive and final all decisions or interpretations of the Com
PDL BioPharma, Inc. Stock Option Agreement (Amended 11/15/19)Stock Option Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Delaware
PDL BioPharma, Inc. (the “Company”) has granted to the Participant named in the Stock Option Grant Notice (the “Notice”) to which this Stock Option Agreement (this “Agreement”) is attached an option (the “Option”) to purchase certain shares of Common Stock upon the terms and conditions set forth in the Notice and this Agreement. The Option has been granted pursuant to and shall in all respects be subject to the terms and conditions of the Company’s Amended and Restated 2005 Equity Incentive Plan (as amended to date, the “Plan”), the provisions of which are incorporated herein by reference. By signing the Notice, the Participant: (a) acknowledges receipt of and represents that Participant has read and is familiar with the Notice, this Agreement and the Plan and the current prospectus for the Plan (the “Prospectus”), (b) accepts the Award subject to all of the terms and conditions of the Notice, this Agreement and the Plan and (c) agrees to accept as binding, conclusive and final all dec
PDL BioPharma, Inc. Stock Option Agreement Amendment AcknowledgmentStock Option Agreement • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances)
The Board of PDL BioPharma, Inc., has on November 15, 2019, amended the Stock Option Agreement applicable to the attached Stock Option Grant Notice(s) (inclusive of the Amended Stock Option Grant Notice(s) corresponding thereto)(the “Notices”), with the intent that amended the amended Stock Option Agreement shall be applicable thereto. The Participant acknowledges, agrees and accepts the amended Stock Option Agreement as governing the awards represented in the attached Notice(s):
FIFTH AMENDMENT TO OFFICE LEASEOffice Lease • March 11th, 2020 • PDL Biopharma, Inc. • Biological products, (no disgnostic substances) • Nevada
This Fifth Amendment to Office Lease ("Fifth Amendment"), effective November 11, 2019, is made by and between Mountain Bluebird Investments, LLC, a Nevada limited liability company, whose principal place of business for the purpose of this Fifth Amendment is 936 Southwood Blvd., Incline Village, Nevada 89451 ("Landlord"), and PDL BioPharma, Inc., a Delaware corporation, whose principal place of business is 932 Southwood Blvd., Suite 101, Incline Village, Nevada 89451 ("Tenant").
